IL17A and infection: Inhibition of this early innate IL-17 produced by γδ T cells, by treatment of mice with IL-17 neutralizing antibodies 1 day prior and 2 days after infection, led to increased bacterial burden at 3 and 7 days post bacterial challenge and this was associated with reduced local production of protective antimicrobial peptides (AMPs) in the lungs [48].